Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature

Vardakas, Konstantinos Z.; Nj, Legakis; Triarides, Nikolaos A.; Falagas, Matthew E.

doi:10.1016/j.ijantimicag.2016.02.001

Cited by 114 publications

(69 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Conversely, a variable susceptibility profile was observed for fosfomycin, depending on enzyme type production and ranged from 27.3% to 81.5%. In a systemic review, the reported susceptibility of fosfomycin in K. pneumomiae, mainly including KPC-producing K. pneumoniae ranged between 39.2% and 100% [36]. Intravenous fosfomycin, a revived antibiotic, has been used in carbapenem resistant Gramnegative infections, but has been associated with rapid development of resistance in vitro, and therefore monotherapy should be avoided [11].…”

Section: Discussionmentioning

confidence: 99%

Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Fosfomycin presented high levels of activity against E. coli. However, this drug was less active against Klebsiella spp., which displayed a higher MIC distribution (21)(22)(23). Falagas et al reported that the fosfomycin MIC distribution can be quite variable and can also be influenced by several factors, including bacterial species (24).…”

Section: Discussionmentioning

confidence: 99%

Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities

Fedrigo

Mazucheli

Albiero

et al. 2017

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Fosfomycin is widely used for the treatment of uncomplicated urinary tract infection (UTI), and it has recently been recommended that fosfomycin be used to treat infections caused by multidrug-resistant (MDR) Gram-negative bacilli. Whether urine acidification can improve bacterial susceptibility to fosfomycin oral dosing regimens has not been analyzed. The MIC of fosfomycin for 245 Gramnegative bacterial isolates, consisting of 158 Escherichia coli isolates and 87 Klebsiella isolates which were collected from patients with urinary tract infections, were determined at pH 6.0 and 7.0 using the agar dilution method. Monte Carlo simulation of the urinary fosfomycin area under the concentration-time curve (AUC) after a single oral dose of 3,000 mg fosfomycin and the MIC distribution were used to determine the probability of target attainment (PTA). Fosfomycin was effective against E. coli (MIC 90 Յ 16 g/ml) but not against Klebsiella spp. (MIC 90 Ͼ 512 g/ml). Acidification of the environment increased the susceptibility of 71% of the bacterial isolates and resulted in a statistically significant decrease in bacterial survival. The use of a regimen consisting of a single oral dose of fosfomycin against an E. coli isolate with an MIC of Յ64 mg/liter was able to achieve a PTA of Ն90% for a target pharmacodynamic index (AUC/MIC) of 23 in urine; PTA was not achieved when the MIC was higher than 64 mg/liter. The cumulative fractions of the bacterial responses (CFR) were 99% and 55% against E. coli and Klebsiella spp., respectively, based on simulated drug exposure in urine with an acidic pH of 6.0. A decrease of the pH from 7.0 to 6.0 improved the PTA and CFR of the target pharmacodynamic index in both E. coli and Klebsiella isolates.KEYWORDS Enterobacteriaceae, fosfomycin, Monte Carlo simulation, acidic pH, pharmacodynamics, urinary tract infection U rinary tract infections (UTIs) are the most common infections worldwide, and members of the family Enterobacteriaceae are the main pathogens responsible for UTIs (1). The rise in the rate of antibiotic resistance over the last several years has resulted in limited treatment options currently available for the treatment of infections caused by multidrug-resistant (MDR) bacteria. Fosfomycin is an old antibiotic agent frequently used to treat uncomplicated UTIs and has been reevaluated as a potential option for the treatment of infections caused by MDR Gram-negative bacteria (2). The dosage currently approved for the treatment of an uncomplicated UTI is a single

show abstract

“…21 Besides, susceptibility patterns of E. coli have remained relatively stable since the introduction of this agent in clinical practice almost 40 years ago. 28 Although fosfomycin is not used as monotherapy for treatment of the P. aeruginosa infection, a study of 228 cases over a period of 12 years showed a significant decline in the susceptibility to fosfomycin over time. 29 This probably because clinically relevant concentrations of fosfomycin combined with other antimicrobial agents enhance bacterial killing of P. aeruginosa, but do not suppress the emergence of fosfomycin resistance.…”

Section: Validation Of the Msw Hypothesis With Fosfomycinmentioning

confidence: 99%

Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study

Pan¹,

Mei²,

Ye³

et al. 2016

J Antibiot

View full text Add to dashboard Cite

Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature

Cited by 114 publications

References 90 publications

Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016

Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016

Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities

Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study

Contact Info

Product

Resources

About